Loading...
XSHE002020
Market cap1.49bUSD
Jan 15, Last price  
12.66CNY
1D
0.48%
1Q
3.86%
Jan 2017
34.20%
Name

Zhejiang Jingxin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002020 chart
P/E
17.61
P/S
2.73
EPS
0.72
Div Yield, %
2.37%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
6.32%
Revenues
4.00b
+5.79%
348,222,229301,881,236428,869,301565,217,329510,305,555531,474,251631,018,882709,730,813857,582,263974,427,3751,235,496,1451,415,696,3561,875,460,9152,219,065,9702,943,801,9953,646,683,9053,258,075,4813,335,970,8893,779,846,2853,998,835,219
Net income
619m
-6.55%
25,790,71918,454,70710,491,2241,503,80603,752,63212,895,45829,119,50831,679,04064,348,188107,080,366165,210,090211,946,309264,376,949370,036,653520,396,181653,070,206612,541,758662,253,823618,898,033
CFO
825m
-3.63%
6,430,29961,820,1390029,983,689135,379,70659,548,10469,412,86860,276,649111,031,750210,488,270144,692,818252,694,495385,007,181523,403,340535,301,257513,210,535365,024,284855,777,798824,691,928
Dividend
May 24, 20240.3 CNY/sh
Earnings
Apr 22, 2025

Profile

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. The company offers APIs, antihypertensive products, antibiotics, quinolones, gastrointestinal promotions, antidiabetics, antipileptics, antihistamines, H+ pump depressants, antihyper cholesterolemia products, histamine H2 receptor blokades, antihyper cholesterolemirs, antidepressants, cephalosporin products, and biopharma products. It also provides diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974 and is headquartered in Xinchang, China.
URL
https://www.jingxinpharm.com/
IPO date
Jul 15, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,998,835
5.79%
3,779,846
13.31%
Cost of revenue
3,064,468
2,984,889
Unusual Expense (Income)
NOPBT
934,367
794,957
NOPBT Margin
23.37%
21.03%
Operating Taxes
84,623
82,493
Tax Rate
9.06%
10.38%
NOPAT
849,744
712,464
Net income
618,898
-6.55%
662,254
8.12%
Dividends
(258,309)
(258,309)
Dividend yield
2.36%
2.47%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
279,091
253,318
Long-term debt
62,455
85,958
Deferred revenue
270,596
Other long-term liabilities
3,203
1,941
Net debt
(1,731,570)
(1,795,017)
Cash flow
Cash from operating activities
824,692
855,778
CAPEX
(519,515)
Cash from investing activities
(769,446)
Cash from financing activities
(245,608)
FCF
177,694
372,338
Balance
Cash
1,611,769
1,915,361
Long term investments
461,347
218,932
Excess cash
1,873,175
1,945,300
Stockholders' equity
3,816,877
3,451,802
Invested Capital
4,249,315
3,690,074
ROIC
21.41%
20.95%
ROCE
15.09%
13.96%
EV
Common stock shares outstanding
859,581
860,070
Price
12.72
4.43%
12.18
28.08%
Market cap
10,933,865
4.37%
10,475,651
34.87%
EV
9,230,076
8,706,482
EBITDA
1,155,834
961,827
EV/EBITDA
7.99
9.05
Interest
9,876
6,015
Interest/NOPBT
1.06%
0.76%